Benefits and adverse events of combined chemotherapy and immune checkpoint inhibition in non-metastatic triple-negative breast cancer: a systematic review and an updated meta-analysis
- 1Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China
Abstract
Background: Previous studies have reported inconsistent findings regarding the efficacy and safety of chemotherapy combined with immune checkpoint inhibitors in patients with non-metastatic triple-negative breast cancer (TNBC). This meta-analysis was designed to assess the clinical benefits and tolerability associated with chemoimmunotherapy in non-metastatic TNBC.
Methods: We conducted a comprehensive search in PubMed, Web of Science, Embase, and the Cochrane Library. The main endpoint is pathological complete response (pCR) rate, with other endpoints of event-free survival (EFS), disease-free survival (DFS) and invasive DFS (iDFS), overall survival (OS), and treatment-related adverse events (AEs).
Results: Data for the meta-analysis came from 8 randomized controlled trials (RCTs). Combining immune checkpoint inhibitors (ICIs) with chemo, they were more effective than chemo in achieving a pCR [odds ratio (OR) =1.82, 95% confidence interval (CI): 1.37–2.41; P<0.001]. The benefit was more pronounced in the group of patients whose lymph nodes were positive (OR =2.19, 95% CI: 1.62–2.96; P<0.001). Regarding OS data, we observed improved EFS with ICI-based regimens [hazard ratio (HR) =0.73, 95% CI: 0.61–0.88; P<0.001]. Although the results of neoadjuvant chemotherapy were found to be statistically significant for iDFS and OS, the adjuvant setting did not demonstrate a similar benefit, and DFS was modestly improved. Safety outcomes showed ≥ Grade 3 AEs were more frequent in the treatment group [relative risk (RR) =1.13, 95% CI: 1.04–1.22; P=0.003], and serious AEs (SAEs) (RR =1.70, 95% CI: 1.49–1.94, P<0.001) among the combination therapy cohorts. The programmed cell death protein 1 (PD-1) inhibitors had more immune-related AEs (irAEs) than the PD-1 ligand (PD-L1) inhibitors. The majority of AEs were controllable in clinical settings, with no additional SAEs being reported.
Conclusions: Combination therapy with ICIs and chemo improves pCR in patients with early-stage or loco-regional TNBC, and may provide better survival benefit.
Related
- Dual Checkpoint Inhibition With or Without Chemotherapy in Metastatic NSCLC: A Reconstructed Individual Patient Data Meta-Analysis.
- Microbiome-derived TOPOSCORE is associated with response to immune checkpoint inhibitor re-induction after chemotherapy in primary resistant metastatic melanoma
- Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy ± bevacizumab for recurrent or metastatic cervical cancer: a systematic review and meta-analysis of randomized controlled trials
- Therapeutic value of PD-1/PD-L1 blockade plus chemotherapy in advanced or metastatic triple-negative breast cancer: a systematic review and meta-analysis of randomized controlled trials.
- Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer
BibTeX
@article{wu2026benefits,
title = {{Benefits and adverse events of combined chemotherapy and immune checkpoint inhibition in non-metastatic triple-negative breast cancer: a systematic review and an updated meta-analysis}},
author = {Jianmin Wu and Kejing Zhang},
journal = {Translational Breast Cancer Research},
year = {2026},
month = jun,
doi = {10.21037/tbcr-2026-0031},
url = {https://doi.org/10.21037/tbcr-2026-0031},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Benefits and adverse events of combined chemotherapy and immune checkpoint inhibition in non-metastatic triple-negative breast cancer: a systematic review and an updated meta-analysis
AU - Jianmin Wu
AU - Kejing Zhang
PY - 2026
DA - 2026/06/24
JO - Translational Breast Cancer Research
DO - 10.21037/tbcr-2026-0031
UR - https://doi.org/10.21037/tbcr-2026-0031
AB - Background: Previous studies have reported inconsistent findings regarding the efficacy and safety of chemotherapy combined with immune checkpoint inhibitors in patients with non-metastatic triple-negative breast cancer (TNBC). This meta-analysis was designed to assess the clinical benefits and tolerability associated with chemoimmunotherapy in non-metastatic TNBC. Methods: We conducted a comprehensive search in PubMed, Web of Science, Embase, and the Cochrane Library. The main endpoint is pathological complete response (pCR) rate, with other endpoints of event-free survival (EFS), disease-free survival (DFS) and invasive DFS (iDFS), overall survival (OS), and treatment-related adverse events (AEs). Results: Data for the meta-analysis came from 8 randomized controlled trials (RCTs). Combining immune checkpoint inhibitors (ICIs) with chemo, they were more effective than chemo in achieving a pCR [odds ratio (OR) =1.82, 95% confidence interval (CI): 1.37–2.41; P<0.001]. The benefit was more pronounced in the group of patients whose lymph nodes were positive (OR =2.19, 95% CI: 1.62–2.96; P<0.001). Regarding OS data, we observed improved EFS with ICI-based regimens [hazard ratio (HR) =0.73, 95% CI: 0.61–0.88; P<0.001]. Although the results of neoadjuvant chemotherapy were found to be statistically significant for iDFS and OS, the adjuvant setting did not demonstrate a similar benefit, and DFS was modestly improved. Safety outcomes showed ≥ Grade 3 AEs were more frequent in the treatment group [relative risk (RR) =1.13, 95% CI: 1.04–1.22; P=0.003], and serious AEs (SAEs) (RR =1.70, 95% CI: 1.49–1.94, P<0.001) among the combination therapy cohorts. The programmed cell death protein 1 (PD-1) inhibitors had more immune-related AEs (irAEs) than the PD-1 ligand (PD-L1) inhibitors. The majority of AEs were controllable in clinical settings, with no additional SAEs being reported. Conclusions: Combination therapy with ICIs and chemo improves pCR in patients with early-stage or loco-regional TNBC, and may provide better survival benefit.
SN - 2218-6778
ER -